Yasunori Kaneko
Angel Investor
San Francisco Bay Area, United States
Yasunori Kaneko is a seed investor in San Francisco Bay Area focused on Biotechnology. Yasunori has been involved in managing and financing US life sciences companies since 1981. He began his career at Genentech (NYSE: DNA), where he spearheaded its business development activities for the first several years. He was then Project Manager for the launch of Protropin (human growth hormone), the first product marketed by Genentech. In1987, he became head of corporate finance in the investment banking division of Paribas Capital Markets LTD in Tokyo, where he helped finance Japanese government agencies, municipalities and corporations in the Euro market. He also helped numerous life sciences companies raise capital. He then became Senior Vice President and CFO of Isis Pharmaceuticals (NASDAQ: ISIS), which went public during his tenure there. In 1992, he was recruited to be the original business executive at Tularik (acquired by Amgen in 2004), where at various times he was CFO and VP-Business Development until its public offering in 1999. He served on the board of LeukoSite until its merger with Millennium Pharmaceuticals (NASDAQ: MLNM) in 1999. He received an undergraduate degree from Keio University in Tokyo, a medical degree from Keio University School of Medicine, and an M.B.A. from Stanford Business School. He joined Skyline in 1999. He committed to golf several years ago after an unfortunate heading incident at a team reunion for his junior All-Star soccer team.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Yasunori Kaneko invests in
Stages Yasunori Kaneko invests in
Countries Yasunori Kaneko invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Logomix Inc is a mammalian cellular genome architect startup. Logomix proprietary platform, Geno-Writing™, technology integrates large-scale (Mb) human genome-writing technologies and providing genetically architected versatile human cells and/or downsized cells and microbes for drug development and cell & gene therapy area.Majority ofthe cell engineering companies are currently focused on optimization of gene clusters by automatic high throughput system however, Logomix’s Geno-Writing™ provides the required tools for dealing with mammalian or complex genomes. Logomix works with partners by providing new biology-based solutions to co-create business and social values on Geno-Writing™ platform Current Focus Area includes: 1. Human Health & Therapeutics 2. Biomaterials & Chemicals 3. Agriculture & EnvironmentLogomix has 11 ongoing collaborative research partnerships. Currently Logomix is specifically looking for industry partners to address unmet needs in neurodegenerative disease areas. | $3.9M / Seed / Feb 07, 2023 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Yasunori Kaneko invest in?
Yasunori Kaneko invests primarily in Biotechnology startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Yasunori Kaneko?
Public channels for Yasunori Kaneko include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Yasunori Kaneko last invest?
The most recent investment recorded for Yasunori Kaneko closed in Feb 2023. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
